Dentsply Sirona Inc SEC Filings

DENTSPLY SIRONA (XRAY) reported a routine insider update: Director Janet S. Vergis acquired 179.449 additional common shares on 10/10/2025, recorded at $0, from dividend equivalents on previously granted restricted stock units (RSUs). The acquisition is coded “A.”

Following the transaction, her beneficial ownership stands at 44,300.167 common shares, held directly. The filing notes these credits reflect RSU dividend equivalents that vest on the same schedule as the related RSUs, with each RSU converting to one share.

DENTSPLY SIRONA (XRAY) reported an insider transaction by SVP, CHRO Andrea Frohning. On 10/10/2025, she acquired 357.053 shares of common stock at $0, representing dividend equivalents on previously awarded RSUs that vest with their underlying awards; each RSU converts to common stock on a 1:1 basis.

She also acquired 22.893 shares of phantom stock under the Supplemental Executive Retirement Plan at a $11.98 derivative security price; phantom stock is economically equivalent to common stock and becomes payable in common stock upon termination of employment. Following these transactions, she beneficially owned 33,609.865 shares of common stock directly and 1,736.5455 phantom stock units directly.

DENTSPLY SIRONA announced that the SEC’s Division of Enforcement has concluded its investigation and does not intend to recommend any enforcement action against the company. The inquiry, initiated by the SEC in connection with an internal review led by the Audit and Finance Committee into certain financial reporting matters raised by employees, began in May 2022 and closed on October 14, 2025. The company had voluntarily contacted the SEC and fully cooperated throughout.

The closure removes a regulatory overhang tied to past financial reporting questions and reflects the regulator’s decision not to pursue action. Management characterized the outcome as a significant and favorable development.

DENTSPLY SIRONA Inc. announced that Richard C. Rosenzweig, Executive Vice President, Corporate Development, General Counsel and Secretary, will step down from that role by mutual agreement effective October 3, 2025. He will serve as a non-executive Special Legal Advisor through a Separation Date no later than March 4, 2026 to transition responsibilities. Under a Transition and Separation Agreement dated October 2, 2025, he is eligible for severance under prior agreements and will receive a monthly fixed fee of $30,000 while Special Legal Advisor; if terminated early without Cause, that amount is payable as if he served through March 4, 2026. After the Separation Date, the Company will engage him as an independent contractor for one year at $20,000 per month. Receipt of these payments is generally contingent on execution of a release and compliance with post-termination covenants. The Transition and Separation Agreement is filed as Exhibit 10.1.

Jonathan Jay Mazelsky, a director of DENTSPLY SIRONA Inc. (XRAY), was granted phantom stock units on 09/30/2025. The Form 4 reports an award of 2,386.165 phantom stock units under the directors' deferred compensation plan, with an indicated price of $12.57 per underlying share. Each phantom share is the economic equivalent of one share of common stock and becomes payable in common stock upon the reporting persons termination of service. After the reported award, the Form shows 11,620.2024 shares beneficially owned by the reporting person in a direct ownership form.

DENTSPLY SIRONA Inc. approved a one-time retention equity award to certain executives, including named executive officer Tony Johnson, Senior Vice President and Chief Supply Chain Officer. The award is a stock option grant with a grant date fair value of $2,000,000 awarded to Mr. Johnson to recognize his performance during recent CEO and CFO transitions and to incentivize retention through the next three years.

The options are expected to be granted on the second trading day after the company files its quarterly report for the fiscal quarter ended September 30, 2025, will cliff-vest on the third anniversary of the grant date provided continuous employment, and will expire on the tenth anniversary. Half of the options will have an exercise price equal to the fair market value on the grant date and half will have an exercise price equal to 110% of that value.

DENTSPLY SIRONA Inc. announced on September 8, 2025 that it completed its previously disclosed review of strategic alternatives for its Wellspect Healthcare business and the Board determined that Wellspect will remain within the Company’s portfolio. The Company furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing notes the exhibit is furnished (not "filed") and therefore is not incorporated by reference into other Securities Act or Exchange Act filings absent specific reference. No financial statements, transaction terms, or forward-looking guidance are included in the provided text.

Lazard Asset Management LLC filed a Schedule 13G reporting ownership of 10,107,657 shares of DENTSPLY SIRONA Inc. (CUSIP 24906P109), representing 5.1% of the outstanding equity as of 06/30/2025. The filer reports sole voting power over 10,002,455 shares and sole dispositive power over 10,107,657 shares. The filing identifies the reporting person as an investment adviser (IA) organized in New York and includes a certification that the securities are not held to change or influence control of the issuer. The filing is signed by Mark Anderson, Managing Director, General Counsel, dated 08/14/2025.

AQR Capital Management and its parent AQR Capital Management Holdings report a material passive stake in DENTSPLY SIRONA Inc. Together they beneficially own 13,316,771 shares of common stock, equal to 6.68% of the class. The filing shows shared voting and shared dispositive power over those shares and records no sole voting or dispositive power.

The Schedule 13G states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing lists the issuer headquarters in Charlotte, NC, gives AQR's Greenwich, CT address, and is signed by an authorized signatory on 08/14/2025. An exhibit notes AQR Capital Management, LLC is wholly owned by AQR Capital Management Holdings, LLC.